Caprock Group LLC Purchases Shares of 1,049 Insulet Co. (NASDAQ:PODD)

Caprock Group LLC bought a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,049 shares of the medical instruments supplier's stock, valued at approximately $274,000.

Other large investors also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its holdings in Insulet by 10.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,000 shares of the medical instruments supplier's stock valued at $202,000 after buying an additional 95 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Insulet in the 2nd quarter valued at approximately $830,000. Czech National Bank lifted its position in Insulet by 7.0% in the third quarter. Czech National Bank now owns 14,283 shares of the medical instruments supplier's stock worth $3,324,000 after purchasing an additional 937 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Insulet by 26.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,683 shares of the medical instruments supplier's stock worth $392,000 after acquiring an additional 347 shares during the period. Finally, Mather Group LLC. raised its position in Insulet by 74.0% in the third quarter. Mather Group LLC. now owns 816 shares of the medical instruments supplier's stock worth $190,000 after purchasing an additional 347 shares in the last quarter.

Insulet Trading Up 0.8 %

PODD traded up $2.26 during mid-day trading on Monday, hitting $285.34. The stock had a trading volume of 411,659 shares, compared to its average volume of 525,241. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The firm has a market capitalization of $20.01 billion, a price-to-earnings ratio of 48.86, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock's fifty day simple moving average is $270.65 and its 200-day simple moving average is $242.24.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.13. The business had revenue of $543.90 million during the quarter, compared to analysts' expectations of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period in the prior year, the business earned $0.71 EPS. As a group, research analysts forecast that Insulet Co. will post 3.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PODD. Raymond James increased their target price on Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Barclays boosted their target price on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. TD Cowen raised their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price objective for the company. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $277.13.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Lauren Budden sold 915 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company's stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.